Efficacy and safety of the weight-loss drug rimonabant.

Anti-Obesity Agents/adverse effects; Depression/chemically induced; Depressive Disorder, Major; Humans; Obesity/drug therapy/psychology; Patient Selection; Piperidines/adverse effects; Pyrazoles/adverse effects; Suicide

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Despres, Jean-Pierre

Van Gaal, Luc

Pi-Sunyer, Xavier

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Language :

English

Title :

Efficacy and safety of the weight-loss drug rimonabant.

Publication date :

2008

Journal title :

The Lancet

ISSN :

0140-6736

eISSN :

1474-547X

Publisher :

Elsevier

Volume :

371

Issue :

9612

Pages :

555; author reply 556-7

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

http://www.sciencedirect.com/science/journal/01406736

Commentary :

All our thanks to Elsevier Science B.V., Amsterdam.

Available on ORBi :

since 26 January 2009

Statistics

Number of views

91 (4 by ULiège)

Number of downloads

280 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Christensen R., Kristensen P., Bartels E., Bliddal H., and Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370 (2007) 1706-1713
Klein D. The flawed basis for FDA post-marketing decisions: the example of anti-depressants and children. Neuropsychopharmacology 31 (2006) 689-699
European Medicines Agency. Acomplia: summary of Product Characteristics. http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/H-666-PI-en.pdf (accessed Nov 21, 2007).